GeneDx Holdings Corp.WGSEarnings & Financial Report
GeneDx is a genetic testing company that was founded in 2000 by two scientists from the National Institutes of Health (NIH), Sherri Bale and John Compton. They started the company to provide clinical diagnostic services for patients and families with rare and ultra-rare disorders, for which no such commercial testing was available at the time. The company started in the Technology Development Center, a biotech incubator supported by the state of Maryland and Montgomery County, MD. In 2006, Bi...
Revenue
$116.7M
Gross Profit
$84.5M
Operating Profit
$-3.3M
Net Profit
$-7.6M
Gross Margin
72.4%
Operating Margin
-2.8%
Net Margin
-6.5%
YoY Growth
51.9%
EPS
$-0.27
GeneDx Holdings Corp. Q3 FY2025 Financial Summary
GeneDx Holdings Corp. reported revenue of $116.7M (up 51.9% YoY) for Q3 FY2025, with a net profit of $-7.6M (up 8.1% YoY) (-6.5% margin). Cost of goods sold was $32.2M, operating expenses totaled $87.8M.
Key Financial Metrics
| Total Revenue | $116.7M |
|---|---|
| Net Profit | $-7.6M |
| Gross Margin | 72.4% |
| Operating Margin | -2.8% |
| Report Period | Q3 FY2025 |
Revenue Breakdown
GeneDx Holdings Corp. Q3 FY2025 revenue of $116.7M breaks down across 4 segments, led by Diagnostic Test Third Party Insurance at $95.0M (81.4% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Diagnostic Test Third Party Insurance | $95.0M | 81.4% |
| Diagnostic Test Institutional Customers | $17.5M | 15.0% |
| Other | $3.2M | 2.8% |
| Fabric Genomics Inc. | $2.0M | 1.7% |
GeneDx Holdings Corp. Revenue by Segment — Quarterly Trend
GeneDx Holdings Corp. revenue by segment across the last 4 reported quarters, showing how each business line (such as Diagnostic Test Third Party Insurance and Diagnostic Test Institutional Customers) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Diagnostic Test Third Party Insurance | $101.1M | $95.0M | $81.1M | $68.1M |
| Diagnostic Test Institutional Customers | $15.5M | $17.5M | $18.4M | $17.6M |
| Other | $3.4M | $3.2M | $2.9M | $1.4M |
| Fabric Genomics Inc. | — | $2.0M | — | — |
GeneDx Holdings Corp. Annual Revenue by Year
GeneDx Holdings Corp. annual revenue history includes year-by-year totals (for example, 2025 revenue was $427.5M).
| Year | Annual Revenue |
|---|---|
| 2025 | $427.5M |
| 2024 | $305.4M |
GeneDx Holdings Corp. Quarterly Revenue & Net Profit History
GeneDx Holdings Corp. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $121.0M | +26.5% | $-17.7M | -14.6% |
| Q3 FY2025 | $116.7M | +51.9% | $-7.6M | -6.5% |
| Q2 FY2025 | $102.7M | +45.6% | $10.8M | 10.5% |
| Q1 FY2025 | $87.1M | +39.6% | $-6.5M | -7.5% |
| Q4 FY2024 | $95.6M | +66.6% | $5.4M | 5.7% |
| Q3 FY2024 | $76.9M | +44.2% | $-8.3M | -10.8% |
| Q2 FY2024 | $70.5M | +44.8% | $-29.2M | -41.4% |
| Q1 FY2024 | $62.4M | +44.7% | $-20.2M | -32.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $62.4M | $70.5M | $76.9M | $95.6M | $87.1M | $102.7M | $116.7M | $121.0M |
| YoY Growth | 44.7% | 44.8% | 44.2% | 66.6% | 39.6% | 45.6% | 51.9% | 26.5% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $394.5M | $389.1M | $408.8M | $419.4M | $446.4M | $463.9M | $493.9M | $523.7M |
| Liabilities | $187.3M | $195.1M | $204.3M | $174.1M | $189.0M | $186.7M | $201.6M | $215.5M |
| Equity | $207.2M | $194.0M | $204.5M | $245.2M | $257.4M | $277.1M | $292.3M | $308.2M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-16.4M | $-4.5M | $-4.4M | $-3.2M | $10.2M | $10.4M | $15.8M | $-3.1M |